International Journal of Risk & Safety in Medicine
The International Journal of Risk and Safety in Medicine is concerned with rendering the practice of medicine as safe as it can be; that involves promoting the highest possible quality of care, but also examining how those risks, which are inevitable, can be contained and managed ideally considering how they can be used when applied to an international audience.
This is not exclusively a drugs journal. As indicated by the journal's subtitle, there is a focus on patient safety, pharmacovigilance and liability. The journal publishes high quality interdisciplinary papers related to patient safety, not ones for domain specialists. Basic research reports of clinical experience and overviews, new items and letters to the editor will be considered for publication. Please see the author guidelines for more information about the article types and requirements.
The journal in particular welcomes submissions about balancing the benefits AND risks of any treatment/management that should be considered by clinical practitioners and which can also aid understanding by patients when agreeing to their clinical care.The International Journal of Risk and Safety in Medicine is concerned with rendering the practice of medicine as safe as it can be; that involves promoting the highest possible quality of care, but also examining how those risks, which are inevitable, can be contained and managed ideally considering how they can be used when applied to an international audience.
This is not exclusively a drugs journal. As indicated by the journal's subtitle, there is a focus on patient safety, pharmacovigilance and liability. The journal publishes high quality interdisciplinary papers related to patient safety, not ones for domain specialists. Basic research reports of clinical experience and overviews, new items and letters to the editor will be considered for publication. Please see the author guidelines for more information about the article types and requirements.
The journal in particular welcomes submissions about balancing the benefits AND risks of any treatment/management that should be considered by clinical practitioners and which can also aid understanding by patients when agreeing to their clinical care.
| Lilya E. Ziganshina | Russian Medical Academy for Continuing Professional Education (RMANPO), Russia |
| Carlo Bottari | University of Bologna, Italy |
| Maxine Gossell-Williams | The University of the West Indies at Mona, Jamaica |
| Federico Laus | University of Bologna, Italy |
| Mecit Can Emre Simsekler | Boston Children’s Hospital, USA |
| Peter R. Breggin | Private Practice of Psychiatry, USA |
| Elliot Brown | Elliot Brown Consulting Ltd, UK |
| Rebecca Chandler | Uppsala Monitoring Centre, Sweden |
| Andrzej Czarnecki | Eli Lilly and Company, UK |
| Edzard Ernst | University of Exeter, UK |
| Ulrich Hagemann | International Society of Pharmacovigilance, Germany |
| Rokuro Hama | Japan Institute of Pharmacovigilance, Japan |
| Ambrose Isah | University of Benin, Nigeria |
| Donald Harvey Marks | University of Pittsburgh, USA |
| Aleksandr Matveev | Russian Medical Academy for Continuing Professional Education (RMANPO), Russia |
| Priscilla Patricia Nyambayo | Munyaradzi Medicines Control, Zimbabwe |
| Emmanuel Okoro | University of Ilorin, Nigeria |
| Abimbola Olowofela-Opadeyi | Univeristy of Benin, Nigeria |
| Elena Rocca | NMBU University, Norway |
| Mulugeta Russom | Eritrean Pharmacovigilance Centre, Eritrea |
| Ruth Savage | University of Otago, New Zealand |
| Abimbola Sundstrom | Karolinska Institutet, Sweden |
| Michael Tatley | Otago University, New Zealand |
| Eugene van Puijenbroek | University Groningen, The Netherlands |
| Mauro Venegoni | University of Verona, Italy |